Abstract
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK), which is transiently expressed during development of the central and peripheral nervous system. ALK has been recently identified as a major neuroblastoma predisposition gene and activating mutations have also been identified in a subset of sporadic neuroblastoma tumors. Two hot spots of ALK mutations have been observed at positions F1174 and R1275. Here, we studied stably transfected cell lines expressing wild-type or F1174L- or R1275Q-mutated ALK in parallel with a neuroblastoma cell line (CLB-GE) in which the allele mutated at position F1174 is amplified. We observed that the mutated ALK variants were essentially intracellular and were largely retained in the reticulum/Golgi compartments. This localization was corroborated by a defect of N-linked glycosylation. Although the mutated receptors exhibited a constitutive activation, the minor pool of receptor addressed to the plasma membrane was much more tyrosine phosphorylated than the intracellular pool. The use of antagonist monoclonal antibodies suggested that the constitutive activity of the mutated receptors did not require the dimerization of the receptor, whereas adequate dimerization triggered by agonist monoclonal antibodies increased this activity. Finally, kinase inactivation of the mutated receptors restored maturation and cell-surface localization. Our results show that constitutive activation of ALK results in its impaired maturation and intracellular retention. Furthermore, they provide a rationale for the potential use of kinase inhibitors and antibodies in ALK-dependent tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Buchwald M, Pietschmann K, Muller JP, Bohmer FD, Heinzel T, Kramer OH . (2010). Ubiquitin conjugase UBCH8 targets active FMS-like tyrosine kinase 3 for proteasomal degradation. Leukemia 24: 1412–1421.
Caren H, Abel F, Kogner P, Martinsson T . (2008). High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J 416: 153–159.
Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971–974.
Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD et al. (2009). Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36: 326–339.
Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al. (2007). Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 104: 270–275.
George RE, Sanda T, Hanna M, Frohling S, Luther II W, Zhang J et al. (2008). Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975–978.
Helenius A, Aebi M . (2004). Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73: 1019–1049.
Honorat JF, Ragab A, Lamant L, Delsol G, Ragab-Thomas J . (2006). SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling. Blood 107: 4130–4138.
Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14: 439–449.
Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. (2008). Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455: 967–970.
Janoueix-Lerosey I, Schleiermacher G, Delattre O . (2010). Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 29: 1566–1579.
Kornfeld R, Kornfeld S . (1985). Assembly of asparagine-linked oligosaccharides. Annu Rev Bioche 54: 631–664.
Lamant L, Pulford K, Bischof D, Morris SW, Mason DY, Delsol G et al. (2000). Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156: 1711–1721.
Lievens PM, Mutinelli C, Baynes D, Liboi E . (2004). The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 279: 43254–43260.
Loren CE, Scully A, Grabbe C, Edeen PT, Thomas J, McKeown M et al. (2001). Identification and characterization of DAlk: a novel Drosophila melanogaster RTK which drives ERK activation in vivo. Genes Cells 6: 531–544.
Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F . (2009). Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158: 1–9.
Mathivet T, Mazot P, Vigny M . (2007). In contrast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (anaplastic lymphoma kinase)? Cell Signal 19: 2434–2443.
Miyake I, Hakomori Y, Shinohara A, Gamou T, Saito M, Iwamatsu A et al. (2002). Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncogene 21: 5823–5834.
Moog-Lutz C, Degoutin J, Gouzi JY, Frobert Y, Brunet-de Carvalho N, Bureau J et al. (2005). Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J Biol Chem 280: 26039–26048.
Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X et al. (1997). ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogen 14: 2175–2188.
Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455: 930–935.
Mosse YP, Wood A, Maris JM . (2009). Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15: 5609–5614.
Motegi A, Fujimoto J, Kotani M, Sakuraba H, Yamamoto T . (2004). ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci 117: 3319–3329.
Mourali J, Benard A, Lourenco FC, Monnet C, Greenland C, Moog-Lutz C et al. (2006). Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol 26: 6209–6222.
Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R . (2005). Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol 167: 213–222.
Palmer RH, Vernersson E, Grabbe C, Hallberg B . (2009). Anaplastic lymphoma kinase: signalling in development and disease. Biochem 420: 345–361.
Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF . (2007). Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/{zeta} signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 282: 28683–28690.
Reiner DJ, Ailion M, Thomas JH, Meyer BJ . (2008). C elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling. Curr Bio 18: 1101–1109.
Schmidt-Arras DE, Bohmer A, Markova B, Choudhary C, Serve H, Bohmer FD . (2005). Tyrosine phosphorylation regulates maturation of receptor tyrosine kinases. Mol Cell Biol 25: 3690–3703.
Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B . (2006). Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 6: 448–461.
Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q et al. (2009). Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer The 9: 331–356.
Yang HL, Eriksson T, Vernersson E, Vigny M, Hallberg B, Palmer RH . (2007). The ligand Jelly Belly (Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK. J Exp Zoolog B Mol Dev Evol 308: 269–282.
Acknowledgements
Work at the Institut du Fer à Moulin UMR-S839 was supported by Inserm and Université Pierre et Marie Curie. The U830 Inserm laboratory is supported by grants from the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisée), the Association Hubert Gouin, Les Bagouz à Manon, les amis de Claire and Enfance et Santé. We are grateful to Dr JA Girault for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Mazot, P., Cazes, A., Boutterin, M. et al. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking. Oncogene 30, 2017–2025 (2011). https://doi.org/10.1038/onc.2010.595
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.595
Keywords
This article is cited by
-
The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
Journal of Experimental & Clinical Cancer Research (2022)
-
Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
Oncogene (2019)
-
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies
Nature Communications (2018)
-
The ALK receptor in sympathetic neuron development and neuroblastoma
Cell and Tissue Research (2018)
-
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors
Journal of Hematology & Oncology (2016)